- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00954005
Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma (R-GO)
August 17, 2015 updated by: Martin Hoffmann, German Low Grade Lymphoma Study Group
Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma
The purpose of the phase I part is to determine the tolerability, the initial safety profile and maximum tolerated dose of oxaliplatin in combination with gemcitabine for indolent lymphoma.
In the phase II part the investigators want to estimate the activity of gemcitabine and oxaliplatin in combination with rituximab for patients with relapsed/refractory indolent lymphoma.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ludwigshafen, Germany, 67063
- Klinikum Ludwigshafen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Need for therapy in patients with relapsed/refractory patients
Histological proven diagnosis of an indolent B-cell lymphoma according to the World Health Organization (WHO) classification belonging to one of the following entities:
- follicular lymphoma
- mantle cell lymphoma
- lymphoplasmacytic lymphoma
- nodal or splenic marginal zone lymphoma
- measurable disease
- lymphoma specific therapy in the last four weeks
- WHO performance grade 0, 1 or 2
Exclusion Criteria
- Patients suitable for high dose therapy
- Transformation in high grade lymphoma
- Leukocytes < 1,5/nl or platelets < 100/nl (except due to lymphoma)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rituximab, Gemcitabine and Oxaliplatin
Drug: Rituximab on day 0 or 1 of each 28-day cycle Drug: Gemcitabine on day 1 and 15 of each 28-day cycle Drug: Oxaliplatin on day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²) of each 28-day cycle
|
Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min.
day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Remission Rate
Time Frame: end of therapy
|
end of therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: 5 years
|
5 years
|
|
Median Overall Survival
Time Frame: 5 years
|
5 years
|
|
Toxicity
Time Frame: 5 years
|
Number of Participants With Treatment-Related Adverse Events as Assessed by WHO Toxicity Grading Scale
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Martin Hoffmann, Dr., German Low Grade Lymphoma Study Group
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2003
Primary Completion (Actual)
June 1, 2011
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
August 4, 2009
First Submitted That Met QC Criteria
August 4, 2009
First Posted (Estimate)
August 6, 2009
Study Record Updates
Last Update Posted (Estimate)
August 19, 2015
Last Update Submitted That Met QC Criteria
August 17, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Gemcitabine
- Oxaliplatin
- Rituximab
Other Study ID Numbers
- 001 (NavyGHB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Indolent Lymphoma
-
Fondazione Italiana Linfomi - ETSActive, not recruitingIndolent B-Cell LymphomasFrance, Italy, Brazil, Austria, Portugal, Ukraine
-
Ludwig-Maximilians - University of MunichHoffmann-La Roche; Janssen-Cilag G.m.b.HActive, not recruitingIndolent Non-Hodgkin LymphomaGermany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Indolent Adult Non-Hodgkin LymphomaUnited States
-
University of Michigan Rogel Cancer CenterBristol-Myers Squibb; Bayer; University of Michigan; Big Ten Cancer Research ConsortiumActive, not recruiting
-
SecuraBioCompletedIndolent Non-Hodgkin LymphomaKorea, Republic of, Czechia, United States, United Kingdom, Italy, Poland, Russian Federation, Germany
-
PrECOG, LLC.Genentech, Inc.TerminatedIndolent Non-Hodgkin's LymphomaUnited States
-
Gruppo Italiano Studio LinfomiUnknown
-
S*BIOCompletedHodgkin Lymphoma | Mantle Cell Lymphoma | Indolent LymphomaUnited States, Canada
-
Shanghai YingLi Pharmaceutical Co. Ltd.Not yet recruitingIndolent B-cell Lymphoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma | Ann... and other conditionsUnited States
Clinical Trials on Therapy with Rituximab, Gemcitabine and Oxaliplatin
-
Zhejiang Cancer HospitalRecruitingDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma RefractoryChina
-
Sun Yat-sen UniversityCompletedLymphoma, Large B-Cell, DiffuseChina
-
University of California, IrvineTerminatedCarcinoma, Transitional CellUnited States
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
-
Grupo Español de Linfomas y Transplante Autólogo...CompletedMantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | Aggressive LymphomaSpain
-
University of ZurichTerminatedPancreatic CancerFrance, Switzerland, Belgium, Germany
-
Eli Lilly and CompanyCompletedLymphoma, Large Cell, DiffuseFrance, Germany, Russian Federation
-
Lymphoma Study AssociationEli Lilly and Company; Hoffmann-La Roche; Sanofi-SynthelaboCompletedDiffuse Large Cell LymphomaFrance
-
Tata Memorial CentreRecruiting
-
3D Medicines (Sichuan) Co., Ltd.RecruitingBiliary Tract NeoplasmsChina